We conducted a meta-analysis which included five randomized controlled phase III trials of first-line therapies for unresectable HCC to show significantly better OS, PFS, ORR and DCR outcomes with PD-1/PD-L1 inhibitors in combination with anti-angiogenic drugs compared with anti-angiogenic drugs alone. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.